Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Immunology Growth Now Hinges On Stelara, Tremfya After RA Setback

Executive Summary

The company said it will pull global regulatory filings for the interleukin-6 inhibitor sirukumab for rheumatoid arthritis after determining regulatory delays would put it too far behind the competition.

Advertisement

Related Content

AML Paradigm Shift: Doctors Welcome Many New Approvals And Approaches
J&J Pharma Growth Led By Oncology; Firm Tries To Assuage Zytiga Concerns
J&J Shows Grace Under Pressure From Biosimilars And Other Threats
J&J Hopes To Reach Market First For Pre-Metastatic Prostate Cancer With Apalutamide
J&J Immunology President On Remicade, Inflectra And The Art Of Contract Negotiations
Keeping Track: An RMAT, Two QIDPs, And Some Bad News Too
Janssen's Sirukumab Falls On Mortality Concerns At US FDA Panel
J&J Prepares For US Sirukumab Launch After Regaining Rights From GSK
J&J's First-In-Class Tremfya Poised To Join A Crowded Psoriasis Market
J&J Forges Ahead In Immunology Despite Competitive Dynamics

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099685

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel